Jolanta Siller-Matula

Summary

Affiliation: Medical University of Vienna
Location: Vienna, Austria

Publications

  1. doi request reprint Ticagrelor: from discovery to Phase III clinical trial
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Future Cardiol 6:753-64. 2010
  2. ncbi request reprint Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Vienna, Austria
    Evid Based Med 16:144-5. 2011
  3. doi request reprint An experimental model to study isolated effects of thrombin in vivo
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 126:454-61. 2010
  4. doi request reprint Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Heart 97:98-105. 2011
  5. doi request reprint Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Clin Res Cardiol 99:645-50. 2010
  6. pmc Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Br J Pharmacol 159:502-17. 2010
  7. doi request reprint Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, and 5th Medical Department, Kaiser Franz Josef Hospital, Vienna, Austria
    J Thromb Haemost 8:351-9. 2010
  8. doi request reprint Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria
    Thromb Haemost 102:397-403. 2009
  9. doi request reprint The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 123:874-80. 2009
  10. doi request reprint Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Am Heart J 157:148.e1-5. 2009

Detail Information

Publications23

  1. doi request reprint Ticagrelor: from discovery to Phase III clinical trial
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Future Cardiol 6:753-64. 2010
    ..However, ticagrelor did not only reduce death due to vascular causes but also all-cause mortality. Further clinical trials in indications other than acute coronary syndrome are awaited...
  2. ncbi request reprint Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Vienna, Austria
    Evid Based Med 16:144-5. 2011
  3. doi request reprint An experimental model to study isolated effects of thrombin in vivo
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 126:454-61. 2010
    ..We hypothesized that protracted intravenous infusion of thrombin at steady state will allow to study isolated thrombin effects in vivo...
  4. doi request reprint Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Heart 97:98-105. 2011
    ..Enhanced platelet inhibition by clopidogrel decreases the risk of ischemic events but carries a risk for a concomitant increase in bleeding...
  5. doi request reprint Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Clin Res Cardiol 99:645-50. 2010
    ..The aim of our study was to compare the tacrolimus-eluting carbon-coated JANUS(®) stent with sirolimus-eluting CYPHER(®) stent for the prevention of symptom-driven clinical end points in a real world clinical setting...
  6. pmc Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Br J Pharmacol 159:502-17. 2010
    ..Whether these potential advantages will translate into clinical advantages will require additional comparisons in properly powered, randomized, controlled trials...
  7. doi request reprint Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, and 5th Medical Department, Kaiser Franz Josef Hospital, Vienna, Austria
    J Thromb Haemost 8:351-9. 2010
    ..As no direct comparison between the two methods has been made so far, we investigated which laboratory approach has a better predictive value for stent thrombosis...
  8. doi request reprint Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria
    Thromb Haemost 102:397-403. 2009
    ..Maximal effects were seen 2 hours after aspirin loading and shorter than 72 hours after clopidogrel loading. In conclusion, aspirin and clopidogrel produce stronger signals in the MEA compared to several other methods...
  9. doi request reprint The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Austria
    Thromb Res 123:874-80. 2009
    ..The aim was to investigate if the inhibition of platelet function by clopidogrel and aspirin is equal at two different time points: immediately after percutaneous coronary intervention (PCI) and one day thereafter...
  10. doi request reprint Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Am Heart J 157:148.e1-5. 2009
    ..As proton pump inhibitors are metabolized to varying degrees by CYP2C19, we hypothesized that the reported negative omeprazole-clopidogrel drug interaction may not be a class effect...
  11. doi request reprint Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    J Am Coll Cardiol 52:1557-63. 2008
    ..Because of the known CYP3A4 inhibition by calcium-channel blockers (CCBs), we hypothesized that there might be a drug-drug interaction between clopidogrel and dihydropyridines in patients with coronary artery disease...
  12. doi request reprint Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Platelets 19:551-4. 2008
    ..This variability can be easily avoided to facilitate comparison of data between different laboratories...
  13. doi request reprint Strain differences in toxic effects of long-lasting isoflurane anaesthesia between Wistar rats and Sprague Dawley rats
    J M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Food Chem Toxicol 46:3550-2. 2008
    ..This indicates that the Wistar rats were more sensitive to a 5 h anaesthesia with isoflurane after a premedication with ketamin/xylazine in the described study design...
  14. ncbi request reprint Interspecies differences in coagulation profile
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 100:397-404. 2008
    ..Moreover, our findings confirm the potential usefulness of pigs as an experimental species to study fibrinolytic pathway and support the usefulness of rabbits as a species for examining platelets...
  15. ncbi request reprint Thienopyridines in cardiovascular disease: focus on clopidogrel resistance
    Jolanta Siller-Matula
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, A 1160 Vienna, Austria
    Thromb Haemost 97:385-93. 2007
    ..Prasugrel is one of the incoming new drugs with high expectations, but other agents might follow in the near future...
  16. doi request reprint Why have studies of tailored anti-platelet therapy failed so far?
    Jolanta M Siller-Matula
    Jolanta Siller Matula, MD, PhD, Department of Cardiology, Medical University of Vienna, Vienna, Austria, Tel 43 1 40 400 4614, Fax 43 1 40 400 4216, E mail
    Thromb Haemost 110:628-31. 2013
    ..Several critical issues regarding the design of these trials, which might in part have led to negative results, are discussed in this article. ..
  17. doi request reprint Response variability to P2Y12 receptor inhibitors: expectations and reality
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Vienna, Austria Electronic address
    JACC Cardiovasc Interv 6:1111-28. 2013
    ..Moreover, this paper discusses randomized trials, which so far have failed to show that tailored antiplatelet therapy improves clinical outcome, and treatment options for patients with high on-treatment platelet reactivity. ..
  18. doi request reprint Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Austria
    Int J Cardiol 167:2018-23. 2013
    ..Clopidogrel non-responsiveness is associated with adverse clinical outcome. We aimed to investigate whether individualized antiplatelet treatment in clopidogrel non-responders is an effective and safe strategy...
  19. doi request reprint Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Austria
    Int J Cardiol 167:430-5. 2013
    ..We aimed to investigate whether high platelet reactivity (HPR) to both aspirin and clopidogrel is a stronger predictor of adverse events compared to isolated HPR to clopidogrel or aspirin...
  20. doi request reprint Continuous thrombin infusion leads to a bleeding phenotype in sheep
    Jolanta M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Austria
    Thromb Res 130:226-36. 2012
    ..In addition to a recognized role in the coagulation cascade and haemostasis, thrombin is known to have multiple functions. We aimed to establish an ovine model to study thrombin effects in vivo...
  21. doi request reprint Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
    J M Siller-Matula
    Department of Cardiology, Medical University of Vienna, Vienna, Austria
    J Thromb Haemost 10:529-42. 2012
    ..Prognostic values of genotyping and phenotyping for assessment of clopidogrel responsiveness have been shown in independent studies...
  22. doi request reprint Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects
    Jolanta M Siller-Matula
    Department of Clinical Pharmacology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 106:1020-33. 2011
    ....